Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000796092 | SCV000935589 | uncertain significance | Nemaline myopathy 2 | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine with aspartic acid at codon 8163 of the NEB protein (p.Asn8163Asp). The asparagine residue is weakly conserved and there is a small physicochemical difference between asparagine and aspartic acid. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with NEB-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001766638 | SCV001991357 | uncertain significance | not provided | 2019-06-13 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Missense variant in a gene in which most reported pathogenic variants are truncating/loss-of-function; Has not been previously published as pathogenic or benign to our knowledge |
Revvity Omics, |
RCV001766638 | SCV003811615 | uncertain significance | not provided | 2020-03-03 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000796092 | SCV002083967 | uncertain significance | Nemaline myopathy 2 | 2021-01-26 | no assertion criteria provided | clinical testing |